Welcome

United States Anti-Obesity Prescription Drug Markets

 

  • Research Code : 5785-01-00-00-00
  • SKU : HC00260-NA-MR_03259
  • Share this :
  • Release Date : 11-Jan-2000
  • Region : North America
  • Request Study Sample

Availability: In stock

 

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

Pay By Invoice

Be the first to review this product



Table of Contents

United States Anti-Obesity Prescription Drug Markets, Executive Summary

Introduction to the Anti-Obesity Prescription Drug Market

Market Overview
Objectives and Purpose
Report Scope and Segmentation
Report Structure
Prevalence of Overweight and Obesity in the U.S. Adult Population

Analysis of Market Engineering Research

Analysis of Market Engineering Research
Major Trends
Drivers Affecting the Anti-Obesity Prescription Drug Market
Restraints Affecting the Anti-Obesity Prescription Drug Market
Reimbursement Trends
Competitive Analysis
Alliances, Acquisitions, and Licensing Agreements
Strategies for Success

United States Anti-Obesity Prescription Drug Markets, Market Engineering Research Methodology

Research Scope

Objectives and Purpose
Report Structure and Market Segmentation

Market Engineering Forecasting Methodology

Overview
Strategic Significance of the Market Engineering Forecast
Judging Credibility and Accuracy of Market Engineering Forecasts
Forecast Assumptions

United States Anti-Obesity Prescription Drug Markets, Industry Challenges

Identification of Challenges Facing the Anti-Obesity Prescription Drug Industry

Identification of Challenges Facing the Anti-Obesity Prescription Drug Industry
Convincing Physicians on the Merits of Anti-Obesity Drugs Drives Market Growth
Convincing Healthcare Providers to Reimburse Prescription Anti-Obesity Drugs Will Stimulate Market Penetration for New Products
The Need for Effective Drugs Forces R&D Innovations
Establishing a Long-Term Drug Efficacy Profile for Weight Maintenance Is Necessary for Continued Market Growth
Improving Drug Side Effect Profile Ensures Persistent Drug Utilization
Educating the General Public on theBenefits of Physician-Mediated Prescription Drug-Use Over Non-Prescription Therapy Nurtures Overall Market Health
Increasing Patient Retention Rates for Anti-Obesity Drugs Enhances Market Expansion
Demonstrating Superior Value Over Generic Phentermine Bolsters New Product Acceptance
Procuring Resources for Marketing Is Necessary for New Product Introduction
Reversing Negative Perceptions of Anti-Obesity Drugs Facilitates Prescription Drug Acceptance

Market Engineering Research for the Anti-Obesity Prescription Drug Market 1998-2006

Market Overview and Definitions

Market Overview
Market Definition
Disease Overview
Scope/Segmentation
History of Anti-Obesity Drugs
Product Overview

Market Engineering Research Measurement System

Market Engineering Research Measurement System

Market Drivers

Market Drivers
New Products Rejuvenate the Market
Magnitude and Increasing Growth Trend of the Overweight and Obese Population Creates Tremendous Market Opportunity
Modest Weight-Loss Provides Significant Health Benefits, Bolstering the Need for Drug Treatments
Acceptance of Obesity as a Chronic Disease Necessitates Long-Term Treatment Approach
Direct-to-Consumer Marketing Increases Awareness of Benefits of Pharmacotherapy
Anti-Obesity Drugs May Have Positive Effects on Other Risk Factors
Off-Label Use of Prescription Drugs Stimulates Market Growth
Increased Awareness of Obesity-Related Healthcare Costs May Force Acceptance of Pharmacotherapy by Healthcare Providers
Progress in the Genetic Understanding of Obesity Spurs Demand
Demand for “Cosmetic” Weight Loss Buoys Overall Market Health

Market Restraints

Market Restraints
Overweight and Obese Patients Do Not Consider Their Excess Weight as a Health Risk
Physicians Are Reluctant to Address Obesity with Their Patients
Failure to Gain Acceptance by Providers and Payors Severely Limits Market Penetration
Effectiveness of Fen/PhenCombination Raises Patient’s Expectations for New Products
High Cost Limits Adoption of New Drugs
Shift from Physician-Controlled Prescription Drug Therapy to Self-Medication Stifles Market
Poor End-User Compliance with Treatment Regimen Limits Market Potential
Inapplicability of Anti-Obesity Drugs to Overweight Patients Without Co-Morbidities Restricts Market Growth
One Month Run-in Period, Which Is Indicative of Drug Effectiveness, Limits Market Expansion
Lack of Established Guidelines for the Treatment of Obesity Restricts Overall Adoption of Pharmacotherapy
Market Engineering and Revenue Forecasts (1998-2006)
Cost Analysis
Revenues

Market Trends

Pricing Trends
Reimbursement Trends
Demographic Trends

Competitive Analysis

Competitive Analysis
Marketing Messages for Meridia and Xenical
Differences in Indications and Contraindications Between Meridia and Xenical
Effects of Meridia and Xenical on Metabolic Parameters
Continual Assessment of Meridia and Xenical in Clinical Studies
Competitive Structure
Alliances, Acquisitions, and Licensing
Market Share Analysis
Market Share Winner and Why
Market Share Loser and Why
Products in Clinical Trials

United States Anti-Obesity Prescription Drug Markets, Research Activities in the Anti-Obesity Therapy Market, 1999

Overview

Overview

Appetite Suppressants

Appetite Suppressants
Leptin
Stimulator of the Leptin Promoter
Leptin Receptor Agonist
Modulator of Leptin Signaling
Ciliary Neurotrophic Factor (CNTF)
Neuropeptide Y (NPY) Receptor Antagonist
POMC/a-MSH
AGRP (Agouti-related Peptide)
Melanin-Concentrating Hormone (MCH)/SLC-1 Receptor
Melanocortin-4 Receptor (MC4-R) Agonist
Corticotropin Releasing Factor (CRF) Receptor Agonists
Galanin Receptor Antagonist
Orexin Receptor Antagonist
Cholecystokinin-A (CCK-A) Receptor Agonist
Glucagon-like Protein-1 (GLP-1) Receptor Agonist
CannaBinoid Receptor Antagonist
CART (Cocaine and Amphetamine Regulated Transcript)
Serotonin Receptor Agonist
Thyroid Hormone Receptor Beta Agonist
Topiramate
P57 (Plant-Based Appetite Suppressant)

Enhancers of Energy Expenditure

Enhancers of Energy Expenditure
ß3-Adrenergic Receptor Agonist
Uncoupling Proteins
Growth Hormone Receptor Agonist

Modulators of Fat Mobilization

Modulators of Fat Mobilization
Peroxisome Proliferator-Activated-Receptors Gamma2 (PPAR-gamma2)
Fatty Acid Transport Protein-4 (FATP4)
Lipase Inhibitor
Enterostatin Agonist
Immunological Therapy

Genes Identified from Rodent Models of Obesity

Genes Identified from Rodent Models of Obesity
mahogany
tub
beacon
Prohormone Convertase-1

Treatments Developed for Diabetes

Treatments Developed for Diabetes

Future Technology Outlook

Future Technology Outlook
The Prospects for Leptin Therapy
The Prospects of Modulating Downstream Targets of Leptin Signaling
The Prospects of Regulating Thermogenesis Through ß3-AR and Uncoupling Proteins
Failed Compounds in Clinical Trials
Future Challenges

United States Anti-Obesity Prescription Drug Markets, Clinical Perspective of Pharmacotherapy for Obesity

Analysis of Clinical Practice

Analysis of Clinical Practice
Diagnosis of Obesity
Demand Analysis
Current Clinical Practices

Future Trends in Clinical Practice

Future Trends in Clinical Practice
Metabolic Fitness as a Result of Drug Therapy

United States Anti-Obesity Prescription Drug Markets, Strategies for Success

Introduction

Introduction

Accessing Technology Through Strategic Alliances and Licensing Agreements

Accessing Technology Through Strategic Alliances and Licensing Agreements

Defend your Innovations

Defend your Innovations

Ensure Reimbursement Through Awareness

Ensure Reimbursement Through Awareness

Develop Physician Education Programs to Increase Market Penetration

Develop Physician Education Programs to Increase Market Penetration

Focus Marketing on Patient-Centric Care

Focus Marketing on Patient-Centric Care

Market Engineering Awards for the Anti-Obesity Prescription Drug Market

Frost & Sullivan's 1999 Market Engineering Awards

Frost & Sullivan's 1999 Market Engineering Awards

Market Engineering Awards

Market Engineering Awards
Award Category: Marketing Strategy
Award Category: Product Differentiation
Award Category: Merger & Acquisition Strategy


Sample Study






Related Research
WHY CHOOSE
FROST & SULLIVAN
RESEARCH ?

1. Primary Research

Our analysis is based on comprehensive primary research conducted with core market participants.

2. Global Coverage

Unparalleled coverage of geographies, our analyst & consultant teams are based in 42+ offices spanning the globe.

3. Breadth of Vertical Industries

We cover the broadest spectrum of markets to provide our clients with the most relevant analysis and transformational insights.

4. Visionary Innovation Research

With on-going transformational shifts, our visionary innovation research prepares you with information on key megatrends shaping the future of your industry.

5. Mega Trends

Mega Trends are global forces that transform business, societies and economies.

6. Convergence Research Coverage

Taking an approach of analysing a macro-to-micro impact, our convergence research helps you prepare against an impending 'Kodak moment'.